Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial.

ABSTRACT:

Background

Biofeedback is an established treatment principle for migraine, but home-based therapy with proven efficacy is not available.

Objective

This study aims to assess the feasibility, usability, and safety of 12 weeks of daily use of a novel medical device (Cerebri; Nordic Brain Tech AS) for therapist-independent multimodal biofeedback preventative treatment in adults with episodic migraine.

Methods

In this open-label, one-armed trial, 20 adult participants with episodic migraine used Cerebri for 12 weeks. The primary outcome was the feasibility of the Cerebri system, measured by the level of adherence to daily biofeedback and electronic headache diary (eDiary) entries. Secondary outcomes were safety, usability, and efficacy.

Results

Initial adherence to

SUBMITTER: Poole AC 

PROVIDER: S-EPMC12169497 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature